Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$12.3B
99M shares
52-week range
$92.77 – $127.99
87% from low
Sector
SERVICES-HOSPITALS
Exchange
NYSE
CS
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
www.encompasshealth.comNo one on the platform currently holds EHC.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 265,000 | $25.6M |
| Bridgewater Associatesas of 2026-03-31 | 46,415 | $4.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-10-01 | $0.2100 | 2026-10-15 |
| 2026-07-01 | $0.1900 | 2026-07-15 |
| 2026-04-01 | $0.1900 | 2026-04-15 |
| 2026-01-02 | $0.1900 | 2026-01-15 |
| 2025-10-01 | $0.1900 | 2025-10-15 |
| 2025-07-01 | $0.1700 | 2025-07-15 |
| 2025-04-01 | $0.1700 | 2025-04-15 |
| 2025-01-02 | $0.1700 | 2025-01-15 |
| 2024-10-01 | $0.1700 | 2024-10-15 |
| 2024-07-01 | $0.1500 | 2024-07-15 |
No one on the platform has traded EHC yet.
| 2024-03-28 | $0.1500 | 2024-04-15 |
| 2023-12-29 | $0.1500 | 2024-01-16 |
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6.4B | +8.3% | $6.04 | $5.81–$6.14 | 20.5× | 9 |
| 2027 | $6.9B | +8.1% | $6.57 | $6.26–$6.72 | 18.8× | 9 |
| 2028 | $7.5B | +8.0% | $7.22 | $6.71–$7.52 | 17.1× | 3 |
| 2029 | $8.2B | +9.6% | $8.37 | $8.33–$8.40 | 14.8× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $1.48 | $1.55 | +4.7% |
| 2026-04-30 | $1.51 | $1.60 | +6.0% |
| 2026-02-05 | $1.29 | $1.46 | +13.2% |
| 2025-10-29 | $1.19 | $1.23 | +3.4% |
| 2025-08-05 | $1.23 | $1.40 | +13.8% |
| 2025-04-24 | $1.19 | $1.37 | +15.1% |
| 2025-02-06 | $1.05 | $1.17 | +11.4% |
| 2024-10-28 | $0.94 |
| $1.03 |
| +9.6% |
| $11.2B |
| — |
| ENSGThe Ensign Group, Inc. | $181.88 | +0.14% | $10.6B | — |
| FMSFresenius Medical Care AG & Co. KGaA | $23.63 | -0.38% | $12.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
TD Cowen analyst Ryan Langston maintained Encompass Health as his top small- and mid-cap pick after the company delivered strong Q2 2026 results, driven by better-than-expected same-facility volume growth and earnings. Adjusted EBITDA reached $348 million, about 3% above consensus, despite an $11.5 million year-over-year headwind from supplemental hospital discharge payments. Revenue rose 10% to $1.60 billion, beating estimates by 2%, while adjusted EPS increased 11% to $1.55, above the $1.49 consensus. Same-facility discharges grew 2.8%, ahead of the 2% estimate, while total discharges rose 5.6%. Encompass Health raised its 2026 adjusted EBITDA guidance by $15 million at both ends of its range and lifted revenue guidance to $6.41-$6.49 billion. Management also authorized a new $1 billion share-repurchase program, while adding 100 beds through facility expansions and new openings. $EHC
View on StockTwits ↗@Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character being 'nutty' $NUTX $EHC
View on StockTwits ↗$EHC Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $1.55 up 9.15% YoY • Reported revenue of $1.6B up 9.58% YoY • Encompass Health increased its full-year 2026 guidance, now projecting net operating revenue of $6.41B to $6.49B, Adjusted EBITDA of $1.365B to $1.395B, and adjusted earnings per share of $6.02 to $6.25.
View on StockTwits ↗$HBM $SMMT $AR $AAL $EHC Hudbay Minerals benefits from copper demand, Summit Therapeutics advances oncology, Antero Resources benefits from natural gas prices, American Airlines continues travel recovery, and Encompass Health leads rehabilitation services.
View on StockTwits ↗Wall St is expecting 1.48 EPS for $EHC Q2 [Reporting 08/04 AMC] http://www.estimize.com/intro/ehc?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗Wall St is expecting 1.48 EPS for $EHC Q2 [Reporting 08/04 AMC] http://www.estimize.com/intro/ehc?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗$EHC Current Stock Price: $99.93 Contracts to trade: $100.0 EHC Jul 17 2026 Call Entry: $2.90 Exit: $5.11 ROI: 76% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗Wall St is expecting 1.48 EPS for $EHC Q2 [Reporting 08/04 AMC] http://www.estimize.com/intro/ehc?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗https://marketbeat.com/a/8708040/ $UNH $HCA $EHC Healthcare Added 35,200 Jobs—3 Stocks Positioned to Benefit
View on StockTwits ↗$EHC Share Price: $105.92 Contract Selected: Dec 18, 2026 $105 Calls Buy Zone: $9.09 – $11.23 Target Zone: $14.85 – $18.15 Potential Upside: 54% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$EHC Price: $104.45 (-0.35%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±0.79% RSI: 55.5 | Momentum: Moderate Volume: -99.0% vs avg Volatility: 2.15% Support: $98.28 | Resistance: $109.32 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
View on StockTwits ↗$EHC Healthcare providers and medical device manufacturers report strong Q1 2026 earnings driven by product approvals, expanded commercial investments, and accelerating procedure volumes with margin expansion from operational efficiency. Learn more: https://axlfi.com/themes/220
View on StockTwits ↗$EHC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.96 up 30.67% YoY • Reported revenue of $1.59B up 9.01% YoY • Encompass Health increased its full-year 2026 guidance, expecting net operating revenue of $6,375 million to $6,470 million, Adjusted EBITDA of $1,350 million to $1,380 million, and adjusted earnings per share of $5.89 to $6.11.
View on StockTwits ↗$EHC Pre-catalyst positioning shows foresight. Post-catalyst stacking shows confirmation. When both happen within 30–60 days, conviction layer doubles. That’s how breakouts get engineered 🚀🔥
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.